Company intelligence / Profile preview
Aptah Bio
San Carlos, California, United Statesaptah-bio.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Aptah Bio is developing a new class of RNA-based therapies that modulate the transcription machinery by targeting U1-snRNP to restore regular gene expression. Their lead compound APT20TTMG has shown recovery of homeostatic protein expression and positive biological effects in cell and animal models. All programs are currently at preclinical stage.
- Therapeutic areas
- OncologyImmunologyRare DiseasesOphthalmologyNeurology
- Modalities
- RNA-based small moleculesChemical drugs
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Aptah Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aptah Bio.